TCTR ID : TCTR20210529001

OTHER ID :

Overall Recruitment Status : Pending (Not yet recruiting)

Prospective registration
This protocol was registered before enrollment of the first participant.

Tracking Information

First Submitted Date :	28 May 2021
First Posted Date :	29 May 2021
Last Update Posted Date :	28 May 2021

Title

Public Title :	Efficacy and applicability of topical cannabidiol-based treatment in psoriasis patient, randomized, placebo, controlled trial
Acronym :	No Data
Scientific Title :	Efficacy and applicability of topical cannabidiol-based treatment in psoriasis patient, randomized, placebo, controlled trial
Sponsor ID/ IRB ID/ EC ID :	043/64
Registration Site :	Thai Clinical Trials Registry
URL :	https://www.thaiclinicaltrials.org/show/TCTR20210529001
Secondary ID :	No Secondary ID

Ethics Review

1. Board Approval :	Submitted, approved
Approval Number :	043/64
Date of Approval :	11 May 2021
Board Name :	Institutional Review Board Faculty of Medicine, Chulalongkorn University
Board Affiliation :	Chulalongkorn University, Thailand
Board Contact :	Business Phone : 022564493 Ext. No Data
	Business Email : medchulairb@chula.ac.th
	Business Address : Institutional Review Board Faculty of Medicine, Chulalongkorn University 1873 RAMA IV ROAD, PATHUMWAN, BANGKOK 10330

Sponsor

Source(s) of Monetary or Material Supports :	Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital
Study Primary Sponsor :	Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital
Responsible Party :	Name/Official Title : Dermatology division, Department of internal medicine
	Organization : King Chulalongkorn Memorial Hospital
	Phone : 022564253 Ext. No Data
	Email : skinchula@gmail.com
Study Secondary Sponsor :	No Study Secondary Sponsor

Protocol Synopsis

Protocol Synopsis :	The plaque type psoriasis patients with mild severity will be recruited to this study. Investigator will select targeted plaques (1-6 plaques) and provide CBD ointment and placebo to all patients. Each plaque will be randomly assigned for different topical treatment. PASI and LPSI are primary outcome. The total treatment period is 12 weeks (baseline, week 2, 4, 8, 12).

URL not available

Health Conditions

Health Condition(s) or Problem(s) Studied :	plaque type psoriasis patients with mild severity
Keywords :	Psoriasis, cannabis, cannabinoid, cannabidiol, marijuana

Eligibility

Inclusion Criteria :	1. male/female 18-70 years 2. plaque type psoriasis, mild severity 3.able to comply with study protocol 4. willingly inform consent

This document was created on 28 November 2026 at 10:20 (GMT+7).

Gender : Both

Age Limit : Minimum : 18 Years Maximum : 70 Years

Exclusion Criteria : 1. unable to stop previous treatment (washout period; systemic treatment 4 weeks, topical treatment 2 weeks). 2. abnormal liver or renal function 3. psychological disorder 4. Pregnant or lactating women 5. allergic to study product.

Accept Healthy Volunteers : No

Status

Overall Recruitment Status : Pending (Not yet recruiting)

Key Trial Dates	Study Start Date (First enrollment) : 01 June 2021	Indicate Type : Anticipated
	Completion Date (Last subject, Last visit) : 01 September 2021	Indicate Type : Anticipated
	Study Completion Date : 01 October 2021	Indicate Type : Anticipated

Design

Study Type : Interventional

Primary Purpose : Treatment

Study Phase : Phase 4

Intervention Model : Parallel

Number of Arms : 2

Masking : Masked Masked Role : Allocation concealment,

Allocation : Randomized

Control : Placebo

Study Endpoint Classification : Safety/Efficacy Study

Sample size

Planned sample size : 30

Intervantion Arm 1

Intervention name : CBD ointment

Intervention Type : Active Comparator

Intervention Classification : Drug

Intervention Description : CBD ointment

Intervantion Arm 2

Intervention name : Placebo

Intervention Type : Placebo Comparator

Intervention Classification : Drug

Intervention Description : Placebo

Outcome

Primary Outcome

1. Outcome Name : PASI

Metric / Method of measurement : PASI

Time point : (baseline, week 2, 4, 8, 12)

Secondary Outcome

1. Outcome Name : Side effects

Metric / Method of measurement : Side effects

Time point : week 2, 4, 8, 12

Location

Section A : Central Contact

Central Contact	First Name : Pravit	Middle Name :	Last Name : Asawanonda
	Degree : MD, DSc	Phone : 0818129393 Ext. : No Data	Email : fibrosis@gmail.com
Central Contact Backup	First Name : Thanaporn	Middle Name :	Lastname : Puaratanaarunkon

	Degree :	Phone : 0898118474 Ext. : No Data	Email : ejikotoey@gmail.com

Section B Facility Information and Contact

1. Site Name : Bhumisiri-Mungklanusorn building (5th Floor Zone C) 1873 Rama 4 Road

	City : Pathumwan	State/Province : bangkok	Postal Code : 10330
	Country : Thailand	Recruitment Status : Pending (Not yet recruiting)	
Facility Contact	First Name : Pravit	Middle Name :	Last Name : Asawanonda
	Degree : MD, DSc	Phone : 0818129393 Ext. : No Data	Email : fibrosis@gmail.com
Facility Contact Backup	First Name : Thanaporn	Middle Name :	Last Name : Puaratanaarunkon
	Degree :	Phone : 0898118474 Ext. : No Data	Email : ejikotoey@gmail.com
Investigator Name	First Name : Pravit	Middle Name :	Last Name : Asawanonda
	Degree :	Role : Principal Investigator	

Section C : Contact for Public Queries (Responsible Person)

First Name : Pravit	Middle Name :	Last Name : Asawanonda
Degree : MD, DSc	Phone : 0818129393 Ext. : No Data	Email : fibrosis@gmail.com
Postal Address : Bhumisiri-Mungklanusorn building (5th Floor Zone C) 1873 Rama 4 Road		
State/Province : Bangkok	Postal Code : 10330	
Country : Thailand	Official Role : Study Principal Investigator	
Organization Affiliation : Chulalongkorn University		

Section D : Contact for Scientific Queries (Responsible Person)

First Name : Pravit	Middle Name :	Last Name : Asawanonda
Degree : MD, DSc	Phone : 0818129393 Ext. : No Data	Email : fibrosis@gmail.com
Postal Address : Bhumisiri-Mungklanusorn building (5th Floor Zone C) 1873 Rama IV Road		
State/Province : Bangkok	Postal Code : 10330	
Country : Thailand	Official Role : Study Principal Investigator	
Organization Affiliation : Chulalongkorn University		

Deidentified Individual Participant-level Data Sharing

Plan to share IPD : No

Reason : Prohibited from regulations

Publication from this study

MEDLINE Identifier : No Data

URL link to full text publication : No Data